ROCHESTER, N.Y., February 24, 2011 â€“ The FDA (Food and Drug Administration) has approved a variance that allows for the sale of KODAK Laser Projector Systems using KODAK Laser Projection Technology to cinema exhibitors without the need for individual site or show operator variances. This is an important step forward in delivering brighter 2D and 3D images that provide higher dynamic range and a wider color gamut to theaters.
â€œThe FDA approval brings KODAK Laser Projection Technology significantly closer to the marketplace and validates the work weâ€™ve done to ensure that this technology is safe and dependable,â€? says Les Moore, Kodakâ€™s chief operating officer for Digital Cinema. â€œIn addition to allowing the sale of KODAK Laser Projector Systems using KODAK Laser Projection Technology, the FDA variance serves as a template to be followed by manufacturers that we license to incorporate this new laser technology.â€?
Typically, digital projection systems using high power lasers fall under the definition of a â€œdemonstration laserâ€? and must follow existing regulations for conventional laser projectors, such as those used in laser light show displays. Kodak has been working in conjunction with laser safety consultants and the FDA to address potential safety issues. The unique optical design of KODAK Laser Projection Technology manages the projector output so that it can be considered to be similar to conventional Xenon projection systems. The FDA variance allows the sale of KODAK Laser Projector Systems with KODAK Laser Projection Technology and theater/show configurations incorporating them. more